Equibles does not estimate personal net worth.
Get an email with a short summary when Axsome Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AXSM alertsNick Pizzie is recorded as CFO at Axsome Therapeutics, Inc. (AXSM). The newest filing on record that lists Nick Pizzie as CFO at Axsome Therapeutics, Inc. (AXSM) is dated April 24, 2026. The proxy statement of Axsome Therapeutics, Inc. reports total compensation of $3,730,519 for Nick Pizzie in fiscal 2025, including a base salary of $530,000. Disclosed compensation is on record for 8 fiscal years. Nick Pizzie has spoken on 26 earnings calls and 9 other investor events across 1 company, most recently for Axsome Therapeutics, Inc. on September 16, 2026. Axsome Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Axsome Therapeutics, Inc. includes Herriot Tabuteau (CEO), Mark Jacobson (COO), Hunter Murdock (General Counsel) and 3 others.
“So for us, state of affairs is mostly status quo on the R&D side. We are seeing more products and earlier stage products that are being identified, discovered, and developed in China that are making their way over to the U.S., either in terms of potential business development efforts.”
“So for us, state of affairs is mostly status quo on the R&D side. We are seeing more products and earlier stage products that are being identified, discovered, and developed in China that are making their way over to the U.S., either in terms of potential business development efforts.”
“As Mark said, it's a unique and exciting time now at Axum. It's really like the next chapter of Axum's story. And I say that because we have the approval and the launch in ADA.”
“I'll begin with a review of our financial results for the quarter. Revenue increased to $218 million compared to $150 million in Q2 of 2025, representing a 46% year-over-year growth.”
“Since five years ago, we looked completely different than where we are today, but I would venture to say five years from today into 2031, we will look even that much more different than where we were five years ago.”
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $530,000 | $3,730,519 |
| 2024 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $505,000 | $3,756,389 |
| 2023 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $485,000 | $3,565,817 |
| 2022 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $451,000 | $3,333,457 |
| 2021 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $409,000 | $4,228,710 |
| 2020 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $375,000 | $2,365,005 |
| 2019 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $325,000 | $1,569,837 |
| 2018 | Axsome Therapeutics, Inc. (AXSM) | C.P.A., M.B.A. Chief Financial Officer | $203,125 | $687,981 |
